• Operating cashflow positive in Q3 FY26 (A$1.2M), significant improvement on Q2 FY26
• Q3 FY26 operating activity payments down 15% in constant currency vs pcp reflecting lower staff and corporate costs
• Accelerated partner program execution with new alliances, key reseller wins, and expanded multi-cloud and international reach

Mach7 Technologies Limited ('Mach7' or the 'Company') (ASX:M7T), a healthcare software company, provides a business update and quarterly cashflow report for the three months ended 31 March 2026. Key highlights include operating cashflow positive in Q3 FY26 (A$1.2M), a significant improvement on Q2 FY26, and Q3 FY26 operating activity payments down 15% in constant currency vs pcp reflecting lower staff and corporate costs. The Company also accelerated its partner program execution with new alliances, key reseller wins, and expanded multi-cloud and international reach. ARR Run Rate was A$22.8M at 31 March 2026, up 2% in constant currency vs 31 December 2025, and CARR was A$25.8M, up 1% in constant currency. The Company has A$19.2M in cash and no debt. FY26 revenue is expected to be approximately 15% below FY25 due to delayed capital deal conversion, particularly in the Middle East, partially offset by an expected ~10% reduction in operating expenses reflecting efficiencies across the business. Mach7 is positioning itself as a core platform for managing and enabling the use of imaging data within complex healthcare environments, with a focus on commercial execution, scalable growth, and strengthening the quality of its revenue base.

FY26 revenue expected to be approximately 15% below FY25 due to reduced services revenue and delays in capital deal conversion in the Middle East. Operating expenses expected to be approximately 10% lower reflecting improved cost control.

FY26 is a transition year for Mach7, with the Company establishing a more predictable, scalable and higher-quality revenue base. Underlying demand remains solid, with a strengthened pipeline and an increasing proportion of ARR-type opportunities. The Company is focused on commercial execution, scalable growth and strengthening the quality of its revenue base.